ORIGINAL ARTICLE

The relationship between Epidermal Growth Factor Receptor (EGFR) mutation and computed tomography findings in lung adenocarcinoma

Agnes Septiani , Pande Putu Ayu Patria Dewi, Anita Widyoningroem, Anggraini Dwi Sensusiati, Muhammad Yamin

Agnes Septiani
Resident of Radiology, Department of Radiology, Faculty of Medicine Airlangga University, Dr. Soetomo Hospital, Surabaya. Email: agnesseptianisp@gmail.com

Pande Putu Ayu Patria Dewi
Department of Clinical Pathology, Faculty of Medicine Udayana University, Bali

Anita Widyoningroem
Department of Radiology, Faculty of Medicine Airlangga University, Dr. Soetomo Hospital, Surabaya

Anggraini Dwi Sensusiati
Department of Radiology, Faculty of Medicine Airlangga University, Dr. Soetomo Hospital, Surabaya

Muhammad Yamin
Department of Radiology, Faculty of Medicine Airlangga University, Dr. Soetomo Hospital, Surabaya
Online First: August 01, 2019 | Cite this Article
Septiani, A., Dewi, P., Widyoningroem, A., Sensusiati, A., Yamin, M. 2019. The relationship between Epidermal Growth Factor Receptor (EGFR) mutation and computed tomography findings in lung adenocarcinoma. Bali Medical Journal 8(2). DOI:10.15562/bmj.v8i2.1428


Background: Adenocarcinoma is the highest histology subtype of lung cancer. Epidermal Growth Factor Receptor (EGFR) is a factor that can predict the prognosis or response to treatment in patients with lung adenocarcinoma. Adenocarcinomas with EGFR mutations generally have a component of Ground Glass Opacity (GGO), smaller size, oval shape, multiple nodal metastases, and distant metastases.  The aim of this study was to determine the relationship between EGFR mutations and CT scan images in pulmonary adenocarcinoma patients.

Methods: This was a retrospective analytical study consisting of 92 samples, which were categorized into the mutation group (n = 62) and wild group (n = 30). This study was conducted at Dr. Soetomo General Hospital from January 2015 – December 2017. The assessed CT-Scan findings were tumor size, shape, density, lymph node size, pleural effusion, and metastasis presence. The relationship was analyzed using the chi-square test and considered significant if the p-value was < 0.05.

Results: This study found a significant relationship between EGFR mutations status with tumor size ≤ 3 cm (p = 0.02), lymph node size < 1.5 cm (p = < 0.001) and metastasis (p = 0.026). However, tumor density, tumor form, and pleural effusion did not have significant relationship with EGFR mutation.

Conclusion: Tumor size ≤ 3 cm, lymph node size < 1.5 cm and presence of metastasis can be found in EGFR mutations pulmonary adenocarcinoma patients.

References

Liu Y, Kim J, Balagurunathan Y, Li Q, Garcia AL, Stringfield O, et al. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. Clin Lung Cancer. 2016; 17(5):441–448.e6.

Hsu K, Chen KC, Yang TY, Yeh YC, Chou TY, Chen HY, et al. Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image. J Thorac Oncol. 2011; 6(6):1066–72.

Hsu JS, Huang MS, Chen CY, Liu GC, Liu TC, Chong IW, et al. Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma. J Thorac Imaging. 2014; 29(6):357–63.

Hong SJ, Kim TJ, Choi YW, Park JS, Chung JH, Lee KW. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes. Eur Radiol. 2016; 26(10):3660–8.

Hasegawa M, Sakai F, Ishikawa R, Kimura F, Ishida H, Kobayashi K. CT features of epidermal growth factor receptor-mutated adenocarcinoma of the lung: Comparison with nonmutated adenocarcinoma. J Thorac Oncol. 2016; 11(6):819–26.

Kemenkes. Stop Kanker. Info Datin Pusat Data dan Informasi Kementerian Kesehatan RI. Jakarta Selatan: Kementerian Kesehatan RI; 2015:1–8.

Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2012; 22(4):796–802.

Halpenny DF, Riely GJ, Hayes S, Yu H, Zheng J, Moskowitz CS, et al. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? Lung Cancer. 2014; 86(2):190–4.

Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. (Eds.). AJCC Cancer Staging Manual. 8th edition. Chicago: Springer; 2017.

Park J, Kobayashi Y, Urayama KY, Yamaura H, Yatabe Y, Hida T. Imaging characteristics of driver mutations in EGFR, KRAS, and ALK among treatment-naïve patients with advanced lung adenocarcinoma. PLoS One. 2016; 11(8):e0161081.

Lee Y, Lee HJ, Kim YT, Kang CH, Goo JM, Park CM, et al. Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: Relationship with epidermal growth factor receptor protein expression status and survival. Korean J Radiol. 2013; 14(2):375–83.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1): 2 – 16.

Remon J, Majem M. EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer : a clue to overcoming resistance. Transl Lung Cancer Res. 2013; 2(6):445–8.

Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB. EGFR testing in advanced non-small-cell lung cancer, a mini-review. Clin Lung Cancer. 2016; 17(6):483–492.

Shi Z, Zheng X, Shi R, Song C, Yang R, Zhang Q, et al. Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma. Sci Rep. 2017; 7:364.

Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2014; 94(2): 129 – 37.

Zhao J, Dinkel J, Warth A, Penzel R, Reinmuth N, Schnabel P. CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation. PLoS One. 2017;12(9):e0182741

Obenauer S, Hermann KP, Grabbe E. Applications and literature review of the BI-RADS classification. Eur Radiol. 2005; 15(5):1027–36.

Khan AN, Al-Jahdali HH, Allen CM, Irion KL, Al Ghanem S, Koteyar SS. The calcified lung nodule: What does it mean? Ann Thorac Med. 2010; 5(2): 67 – 79.

Baldi L, Mengoli MC, Bisagni A, Banzi MC, Boni C, Rossi G. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer. 2014; 86(2): 291 – 5.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0